ProCE Banner Activity

ASH 2020 Preview: Key Expert-Selected Immune Thrombocytopenia Studies

Clinical Thought
Look for these important ITP studies at the upcoming ASH 2020 virtual meeting. Be sure to also attend our ASH 2020 ITP Webinar and check our Web site frequently for downloadable PowerPoint slides featuring key presented data.

Released: November 24, 2020

Expiration: November 23, 2021

Share

Faculty

David J. Kuter

David J. Kuter, MD, DPhil

Professor of Medicine
Massachusetts General Hospital Cancer Center
Harvard Medical School
Hematology Program Director
Massachusetts General Hospital Cancer Center
Massachusetts General Hospital
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Dova Pharmaceuticals

Faculty Disclosure

Primary Author

David J. Kuter, MD, DPhil

Professor of Medicine
Massachusetts General Hospital Cancer Center
Harvard Medical School
Hematology Program Director
Massachusetts General Hospital Cancer Center
Massachusetts General Hospital
Boston, Massachusetts

David J. Kuter, MD, DPhil, has disclosed that he has received funds for research support from Actelion (Syntimmune), Agios, Alnylam, Amgen, Argenx, Bristol-Myers Squibb, Immunovant, Kezar, Principia, Protalex, Rigel, Takeda (Bioverativ), and consulting fees from Actelion (Syntimmune), Agios, Alnylam, Amgen, Argenx, Bristol-Myers Squibb, Caremark, CRICO, Daiichi Sankyo, Dova, Genzyme, Immunovant, Incyte, Kyowa-Kirin, Merck Sharp & Dohme, Momenta, Novartis, Pfizer, Platelet Disorder Support Association, Principia, Protalex, Protalix, Rigel, Sanofi, Genzyme, Shionogi, Shire, Takeda (Bioverativ), UCB, and Zafgen.